Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)

Fred Saad, Kim N. Chi, Neal D. Shore, Julie N. Graff, Edwin M. Posadas, Jean Baptiste Lattouf, Byron M. Espina, Eugene Zhu, Alex Yu, Anasuya Hazra, Marc De Meulder, Rao N.V.S. Mamidi, Branislav Bradic, Peter Francis, Vinny Hayreh, Arash Rezazadeh Kalebasty

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Fingerprint

Dive into the research topics of 'Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds